| Literature DB >> 26126501 |
Sarah A Hopps1, Emily B Borders2, Tracy M Hagemann2.
Abstract
Sinusoidal obstruction syndrome, a complication occurring early after hematopoietic stem cell transplantation, is a concern for clinicians. There are no guidelines to direct clinicians on the optimal way to prevent and treat this disease. Newer data show that defibrotide is a promising drug both for prevention and treatment, although it is not yet FDA approved.Entities:
Keywords: Sinusoidal obstructive syndrome; defibrotide; ursodiol; veno-occlusive disease
Mesh:
Substances:
Year: 2015 PMID: 26126501 DOI: 10.1177/1078155215591387
Source DB: PubMed Journal: J Oncol Pharm Pract ISSN: 1078-1552 Impact factor: 1.809